Company News
TD Cowen Upgrades Axsome Therapeutics PT $300
TD Cowen reiterates a 'buy' rating on Axsome Therapeutics, naming it among its Best Smidcap Ideas for 2026.
TD Cowen raises the price target to $300 from $275, implying upside from the June 16 closing
